Antivitamin K drugs in stroke prevention

Current Vascular Pharmacology

Volumn 11, Issue 6, 2013, Pages 817-823

  di Raimondo, Domenico ^a   Tuttolomondo, Antonino ^a   Buttà, Carmelo ^a   Lucifora, Benedetto ^a   Licata, Giuseppe ^a   Pinto, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiac embolism; Prevention; Stroke; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CLOPIDOGREL; COUMARIN; DABIGATRAN; DIPYRIDAMOLE; EDOXABAN; INDOBUFEN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ARTICLE; BLOOD PRESSURE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; COLONOSCOPY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STENOSIS; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ANTICOAGULANTS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VITAMIN K;

EID: 84893450271     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111106140128113404     Document Type: Article

References (49)

1. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
2. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377(9778): 1681-92.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin k antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 160S-198S.
4. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968; 38: 169-177.
5. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants versus aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002; 288: 2441-8.
6. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. JACC 2009; 54: 999-1002.
7. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14: 469-77.
8. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatric Med 2001; 17: 1-13.
9. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
10. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.
11. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115-24.
12. Gorter JW. For the Stroke Prevention In Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) study groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999; 53: 1319-27.
13. Elkind MS. Anticoagulation for secondary stroke prevention: another nail in the coffin? Lancet Neurol 2007; 6: 97-9.
14. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352(13): 1305-16.
15. Bogousslavsky J, Cachin C, Regli F, et al. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: the Lausanne Stroke Registry. Neurology 1991; 41: 855-9.
16. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92: 17-40.
17. Brickner ME. Cardioembolic stroke. Am J Med 1996; 100: 465-74.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
19. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
20. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
21. The Boston area anticoagulation trial for atrial fibrillation (BAATAF) investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
22. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med 1992; 327: 1406-12.
23. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18(2): 349-55.
24. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
25. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-76.
26. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
27. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003; 3: CD000185.
28. Singer DE, Chang U, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
29. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
30. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-98.
31. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-98.
32. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
33. Freeman JV, Zhu RP, Owens DK, et al. Cost-eff ectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
34. ACTIVE Writing Group. Clopidogrel plus aspirin versus oral anticoagulation for atrial fi brillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12.
35. Diener HC. For the Executive Steering Committee of SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21: 279-93.
36. AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 315-21.
37. Boulander L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006; 60: 258-64.
38. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major haemorrhage and tolerability of warfarin in the fi rst year of therapy among elderly patients with atrial fi brillation. Circulation 2007; 115: 2689-96.
39. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis. Ann Intern Med 1999; 131: 492-501.
40. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-39.
41. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-91.
42. The European Atrial Fibrillation Trial (EAFT) Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
43. Stroke Prevention in Atrial Fibrillation Investigators. Adjusteddose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-38.
44. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28: 1015-21.
45. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367 (9526): 1903-12.
46. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.
47. Delaney JA, Opatrny L, Brophy JA, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-51.
48. Gorelick PB. Combining aspirin with oral anticoagulant therapy. Is this a safe and effective practice in patients with atrial fibrillation? Stroke 2007; 38: 1652-54.
49. Lip GYH. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008; 336: 614-15.